{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:33:40Z","timestamp":1780630420015,"version":"3.54.1"},"reference-count":25,"publisher":"Royal College of Psychiatrists","issue":"6","license":[{"start":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T00:00:00Z","timestamp":1514937600000},"content-version":"unspecified","delay-in-days":7521,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1997,6]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Citalopram is a serotonin reuptake inhibitor which has been demonstrated to be highly selective and with a superior tolerability profile to the classical tricyclic antidepressants. This study was designed to test whether there was any difference in eff icacy in the management of panic disorder (PD) between Citalopram and placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>This was a double-blind, placebo and clomipramine controlled, parallel group eight-week study. A total of 475 patients with PD, with or without agoraphobia, were randomised to treatment with either placebo, clomipramine 60 or 90 mg\/day, or Citalopram 10 or 15 mg\/day, 20 or 30 mg\/day, or 40 or 60 mg\/day. Doses were increased over the first three weeks, stabilised during the fourth week and fixed between weeks five and eight.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment with Citalopram at 20 or 30 mg, 40 or 60 mg and clomipramine were significantly superior to placebo, judged by the number of patients free of panic attacks in the week prior to the final assessment. All rating scales examined suggested that Citalopram 20 or 30 mg was more effective than Citalopram 40 or 60 mg.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The most advantageous benefit\/risk ratio for the treatment of PD was associated with citalopram 20 or 30 mg\/day.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.170.6.549","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T01:36:56Z","timestamp":1224034616000},"page":"549-553","source":"Crossref","is-referenced-by-count":110,"title":["The effect of Citalopram in panic disorder"],"prefix":"10.1192","volume":"170","author":[{"given":"A. G.","family":"Wade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Lepola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J.","family":"Koponen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"S0007125000259059_ref8","first-page":"321","article-title":"Effect of fluvoxamine on panic disorder","volume":"13","author":"Hoehn-Sark","year":"1993","journal-title":"Journal of Clinical Psychopharmocology"},{"key":"S0007125000259059_ref15","doi-asserted-by":"publisher","DOI":"10.1007\/BF02219714"},{"key":"S0007125000259059_ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1985.tb02601.x"},{"key":"S0007125000259059_ref10","first-page":"271","article-title":"The pharmacology of Citalopram","volume":"6","author":"Hyttel","year":"1995","journal-title":"Reviews in Contemporary Pharmacotherapy"},{"key":"S0007125000259059_ref17","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199208000-00007"},{"key":"S0007125000259059_ref21","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.167.3.374"},{"key":"S0007125000259059_ref2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1987"},{"key":"S0007125000259059_ref16","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.162.6.776"},{"key":"S0007125000259059_ref23","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.141.5.518"},{"key":"S0007125000259059_ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199206005-00003"},{"key":"S0007125000259059_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(88)90072-9"},{"key":"S0007125000259059_ref3","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"S0007125000259059_ref5","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800290027004"},{"key":"S0007125000259059_ref22","volume-title":"The Anxiety Disease","author":"Sheehan","year":"1979"},{"key":"S0007125000259059_ref1","first-page":"301","article-title":"Alprazolam treatment for panic disorders","volume":"47","author":"Alexander","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000259059_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/0924-977X(95)90331-7"},{"key":"S0007125000259059_ref18","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"S0007125000259059_ref24","first-page":"238","article-title":"Clonazepam in the treatment of panic disorder and agoraphobia","volume":"47","author":"Spier","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000259059_ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"S0007125000259059_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0924-977X(92)90031-3"},{"key":"S0007125000259059_ref12","doi-asserted-by":"publisher","DOI":"10.3109\/08039489409078121"},{"key":"S0007125000259059_ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1991.tb03097.x"},{"key":"S0007125000259059_ref6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1192\/bjp.160.2.191","article-title":"Drug treatment of panic disorder","volume":"160","year":"1992","journal-title":"British Journal of Psychiatry"},{"key":"S0007125000259059_ref19","first-page":"297","article-title":"Citalopram in the treatment of depression","volume":"6","author":"Montgomery","year":"1995","journal-title":"Reviews in Contemporary Pharmacotherapy"},{"key":"S0007125000259059_ref25","volume-title":"WHO Adverse Reaction Terminology","year":"1989"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000259059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T16:56:14Z","timestamp":1557593774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000259059\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1997,6]]}},"alternative-id":["S0007125000259059"],"URL":"https:\/\/doi.org\/10.1192\/bjp.170.6.549","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,6]]}}}